Latest News
In This Issue:
- FDA Approves First-of-its-Kind Glaucoma Treatment
- President’s Corner
- AI Identifies New Genetic Targets for Glaucoma Treatment
- Six Common Glaucoma Eye Tests
- And more!
Alzheimer’s Disease Research, a BrightFocus Foundation program, was on the ground at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia to share insights on the latest research and foster scientific collaboration. Catch up on a few of the top headlines from AAIC.
In glaucoma, problems with mitochondria—a source of cell energy—can damage neurons that carry visual information from the eyes to the brain. Adriana Di Polo, PhD, is testing small molecule drugs that may prevent this damage and boost energy production in these neurons.
A new BrightFocus-funded study of cognitively healthy 100-year-olds sheds light on genetic characteristics that protect the brain.
Increased eye inflammation with age may contribute to macular degeneration and present differently between sexes, suggests a new BrightFocus-funded study.
Another disease-modifying Alzheimer's therapy hits the market.
On June 10, the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that Eli Lilly’s Alzheimer’s drug, donanemab, is effective for treating early symptomatic Alzheimer’s disease.
In This Issue:
- President’s Corner
- Exercise-Induced Hormone Could Treat Alzheimer’s Disease
- Researcher Spotlight: Ariel Gilad, PhD
- Tips for Managing Caregiver Stress
- Zoom In on Dementia & Alzheimer’s
- Help Fight Alzheimer’s Through a Will or Bequest
In response to overwhelming interest in its first six episodes, four additional episodes of Zoom In on Dementia & Alzheimer’s will walk participants through specific Alzheimer’s clinical trials and research studies.
BrightFocus Foundation hosted its inaugural Concert for Cures on Wednesday, June 26, at City Winery in Nashville.